Skip to main content

GHRH (1–44) vs GHRP-6

Both GHRH (1–44) and GHRP-6 are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.

GHRH (1–44)

Evidence A

Growth Hormone Releasing Hormone, full sequence

The full 44-amino-acid GHRH sequence. The natural pituitary stimulus for GH release. Largely supplanted in clinical use by sermorelin/tesamorelin but remains a research and diagnostic tool.

View full GHRH (1–44) profile →

GHRP-6

Evidence B

Growth Hormone Releasing Peptide 6

An older GHS that produces strong appetite stimulation in addition to GH release. Largely supplanted by Ipamorelin and GHRP-2 for clinical use but still common in research stacks.

View full GHRP-6 profile →

Side-by-Side

AttributeGHRH (1–44)GHRP-6
Evidence GradeAB
FDA StatusFDA-approved (Geref) historically as diagnostic GH stimulant; current US availability limitedNot FDA-approved — research compound
Typical Dose1 mcg/kg IV (diagnostic test)100–300 mcg, 1–3 times daily (subcutaneous)
Clinics Indexed2264
Categoriesgrowth-hormonegrowth-hormone, appetite

Key reported benefits — GHRH (1–44)

  • Endogenous GH stimulation
  • Diagnostic GH testing

Key reported benefits — GHRP-6

  • GH release
  • Appetite stimulation
  • Cytoprotection

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons